Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel oncology and hematology therapeutics to meaningfully improve patientsâ lives. Aptevo has a commercial product, IXINITYÂŽ coagulation factor IX (recombinant), approved and marketed in the United States for the treatment of Hemophilia B, and a versatile core technology â the ADAPTIR⢠modular protein technology platform capable of generating highly-differentiated bispecific antibodies with unique mechanisms of action to treat cancer and autoimmune diseases. Source
No articles found.
Today's adults juggle caring for aging parents and children while working full-tim...
Today's adults juggle caring for aging parents ...
MintHealth is a global, decentralized health platform that aligns healthcare stake...
MintHealth is a global, decentralized health pl...
bluebird bio is pioneering gene therapy with purpose. From our Cambridge, Mass., h...
bluebird bio is pioneering gene therapy with pu...
Inogenâs mission to improve the quality of life of supplemental oxygen users beg...
Inogenâs mission to improve the quality of li...
OpGen, Inc. is a precision medicine company harnessing the power of molecular diag...
OpGen, Inc. is a precision medicine company har...
Precipio has built a platform designed to eradicate the problem of misdiagnosis by...
Precipio has built a platform designed to eradi...
OncoSec Medical Incorporated is a clinical-stage biotechnology company focused on ...
OncoSec Medical Incorporated is a clinical-stag...
Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates...
Merck KGaA, Darmstadt, Germany, a leading scien...
Immuron Ltd is a publicly listed Australian biopharmaceutical company focused on o...
Immuron Ltd is a publicly listed Australian bio...
Founded 20 years ago, Seattle Genetics was built on a foundation of scientific inn...
Founded 20 years ago, Seattle Genetics was buil...
Join the National Investor Network and get the latest information with your interests in mind.